Innovative static culturing method developed
The alternative liquid culturing method does not require shaking of microorganisms, according to the research.
List view / Grid view
The alternative liquid culturing method does not require shaking of microorganisms, according to the research.
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
The Chapter for endotoxin testing using non-animal derived reagents will help quality professionals ensure the safety of sterile pharmaceutical products.
Research and innovation is highlighted in the UK’s Autumn Budget as a priority ‘crucial national asset’ to aid long-term economic growth.
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.
The deal will help AbbVie to strengthen its neuroscience pipeline, including supporting development of next-generation therapies for delivery into the central nervous system.
The 3D printing study enabled a precise tablet structure to be created, allowing for easy modification and for the control of drug release rate through changing the surface curvature.
The funding aims to reduce the costs of AAV production for gene therapies, helping to accelerate treatment access for patients with rare diseases.
Increased adoption of artificial intelligence (AI) and machine learning (ML) in microbiology is set to be a key driver of the global automated microbiology market to 2033, research asserts.
The US FDA has authorised the first treatment for haemophilia A or B that is administered via a pre-filled pen or syringe.
The draft strategy, open for an eight-week public consultation, will help guide the direction of the network over the next few years.
Gill Lewis, QP and Chief GMP Consultant, eXmoor Pharma. discusses the company's approach to environmental monitoring and the key challenges faced during integration at its Cell and Gene Therapy Centre in Bristol, a facility which received a GMP license from the MHRA in August.
The new appointee will create AI and machine learning solutions to support Eli Lilly’s medicines for patients globally.
CPHI Milan takes place in October, covering a wide range of topics from packaging and drug delivery to integrated pharma.
More than half of the multiple myeloma patients included in this study would have been ineligible for the Phase II CARTITUDE-1 clinical trial, research reports.